New hope for advanced cancer patients: experimental drug CKD-512 enters human trials

This early-stage study tests a new drug called CKD-512, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 60 participants will take part to see if the drug shows promise in controlling the disease.